NasdaqGM:NTLABiotechs
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?
In recent weeks, Intellia Therapeutics reported long-term Phase 1/2 data for its CRISPR-based HAE candidate lonvoguran ziclumeran and regained FDA clearance to resume Phase 3 testing of its ATTR-CM therapy nexiguran ziclumeran after agreeing to enhanced liver safety monitoring.
Together, these updates highlight Intellia’s push to position one-time in vivo gene-editing treatments as alternatives to chronic therapies in serious genetic diseases.
Building on the FDA’s removal of the clinical...